Department of Urology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, P.O. Box: 71345-1798, Shiraz, Iran.
BMC Urol. 2022 Aug 29;22(1):133. doi: 10.1186/s12894-022-01085-6.
The significance of total and specific subpopulations of tumor-infiltrating lymphocytes (TILs) in cancer is now well-documented. In the present study, we investigated the relevance of CD3+, CD8 +, CD45RO +, and FOXP3 + TILs to the prognosis and survival of patients with bladder cancer and the disease's clinical-pathological parameters.
Infiltration of each subset was immunohistochemically evaluated in both stromal and intratumoral regions of tumor tissues from 85 patients with urothelial cell carcinoma of the bladder, with known survival.
Our results indicated that intratumoral CD45RO+ lymphocytes were significantly higher in high-grade tumors than in low-grade ones (P = 0.028). The frequencies of intratumoral CD3+ (P = 0.002), CD8 + (P = 0.008), intratumoral (P = 0.002), and stromal (P = 0.017) CD45RO+ lymphocytes were also higher in patients with muscular invasion than those without invasion. The frequencies of intratumoral CD3+ (P = 0.043), CD8+ (P = 0.003), CD45RO+ (P = 0.023), and total CD45RO+ (P = 0.015), showed variation in patients with different T-stage, as well; mostly increased in T2 versus Ta and T1. Comparing patients in different stages revealed an increase in the frequencies of total CD3+ (P = 0.011), intratumoral CD3+ (P = 0.006), total CD8+ (P = 0.012), intratumoral CD8+ (P = 0.009) and stromal CD8+ (P = 0.034), as well as total and stromal CD45RO+ lymphocytes (P = 0.01 and P = 0.034, respectively) in stage II comparing to stage I, while the frequencies of stromal CD3+ (P = 0.077) and CD8+ (P = 0.053) cells tended to be decreased in stage III compared to stage II.
We collectively observed that the frequency of immune cells, especially CD45RO+, CD3+, and CD8+ lymphocytes, were significantly higher in early-progressed tumors. This observation could be explained by continuous and prolonged stimulation of immune cells with tumor antigens during tumor progression or an increase in the recruiting factors, especially in the early stages, to eliminate tumor cells. However, with tumor progression to the late stages, the inhibitory microenvironment provided by tumor cells suppresses or changes the functionality of the effector and memory immune cells to help tumor growth. However, more functional studies with larger sample sizes are needed to reveal the real status of the immune system in patients with bladder cancer.
肿瘤浸润淋巴细胞(TILs)的总量和特定亚群在癌症中的意义现在已经得到充分证明。在本研究中,我们研究了 CD3+、CD8+、CD45RO+和 FOXP3+TILs 与膀胱癌患者的预后和生存以及疾病的临床病理参数的相关性。
对 85 例膀胱癌患者肿瘤组织的间质和肿瘤内区域进行了 CD3+、CD8+、CD45RO+和 FOXP3+TIL 浸润的免疫组织化学评估,这些患者的生存情况已知。
我们的结果表明,高级别肿瘤中肿瘤内 CD45RO+淋巴细胞的比例明显高于低级别肿瘤(P=0.028)。与无肌层浸润的患者相比,肌层浸润的患者肿瘤内 CD3+(P=0.002)、CD8+(P=0.008)、肿瘤内(P=0.002)和间质(P=0.017)CD45RO+淋巴细胞的频率也更高。肿瘤内 CD3+(P=0.043)、CD8+(P=0.003)、CD45RO+(P=0.023)和总 CD45RO+(P=0.015)的频率在不同 T 分期的患者中也存在差异;主要在 T2 期与 Ta 和 T1 期之间增加。比较不同分期的患者发现,总 CD3+(P=0.011)、肿瘤内 CD3+(P=0.006)、总 CD8+(P=0.012)、肿瘤内 CD8+(P=0.009)和间质 CD8+(P=0.034)的频率增加,总和间质 CD45RO+淋巴细胞(P=0.01 和 P=0.034,分别)在 II 期比 I 期增加,而间质 CD3+(P=0.077)和 CD8+(P=0.053)细胞的频率在 III 期比 II 期降低。
我们共同观察到,在进展较早的肿瘤中,免疫细胞,特别是 CD45RO+、CD3+和 CD8+淋巴细胞的频率明显升高。这种观察结果可以用肿瘤进展过程中肿瘤抗原持续和长期刺激免疫细胞或增加募集因子来解释,特别是在早期阶段,以消除肿瘤细胞。然而,随着肿瘤进展到晚期,肿瘤细胞提供的抑制性微环境抑制或改变效应和记忆免疫细胞的功能,以帮助肿瘤生长。然而,需要更多具有更大样本量的功能研究来揭示膀胱癌患者免疫系统的真实状态。